Low Dose Radiation Therapy for COVID-19 Infection

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Emory University Hospital/Winship Cancer Institute, Atlanta, GACOVID-19 Infection+2 MoreLow Dose Radiation Therapy - Radiation
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial compares low dose whole lung radiation therapy to best supportive care and physician's choice in treating patients with COVID-19 infection. Low dose whole lung radiation therapy may work better in improving patients' clinical status, the radiographic appearance of their lungs, or their laboratory blood tests.

Eligible Conditions
  • Symptomatic COVID-19 Infection
  • Coronavirus (COVID-19)
  • Pneumonia

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 36 Secondary · Reporting Duration: Up to follow-up day 14 after study start; This may be extended to 28 days after preplanned interim analysis.

Day 14
Changes on computed tomography (CT) scans pre and post RT
Day 14
ALT
Albumin
Aspartate aminotransferase (AST)
Blood gases pH(when available)
CRP
Changes in CD4 T cells
Changes in CD8 T cells
Changes in serum antibodies against COVID-19 epitope
Creatine kinase
D-Dimer
Ferritin
Fibrinogen
Gamma-glutamyl transferase (GGT)
Glasgow Comma Scale from minimum of 3 to maximum of 15.
Heart rate
IL-6
LDH
Lactate
Myoglobin
NT-pBNP (cardiac injury)
Oxygen saturation
Performance status
Potassium
Procalcitonin
Prothrombin time (PT)/partial thromboplastin time (PTT)
Respiratory rate
Serum chemistry + complete blood cell (CBC) with differential
Supplemental oxygenation need
Systolic Blood pressure
Temperature
Time to clinical recovery
Triglycerides
Troponin
Day 14
Serial chest x-rays severe acute respiratory syndrome (SARS) scoring
Day 28
Survival
Day 28
Freedom from ICU admission

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Arm I (physician choice)
1 of 2
Arm II (LDRT)
1 of 2

Active Control

Experimental Treatment

52 Total Participants · 2 Treatment Groups

Primary Treatment: Low Dose Radiation Therapy · No Placebo Group · Phase 3

Arm II (LDRT)
Radiation
Experimental Group · 1 Intervention: Low Dose Radiation Therapy · Intervention Types: Radiation
Arm I (physician choice)
Other
ActiveComparator Group · 1 Intervention: Best Practice · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to follow-up day 14 after study start; this may be extended to 28 days after preplanned interim analysis.

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,525 Previous Clinical Trials
2,714,369 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,153 Previous Clinical Trials
41,162,256 Total Patients Enrolled
18 Trials studying COVID-19 Infection
77,522 Patients Enrolled for COVID-19 Infection
Mohammad K Khan, MD, PhDPrincipal InvestigatorEmory University Hospital/Winship Cancer Institute
1 Previous Clinical Trials
10 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have recently had severe respiratory symptoms such as difficulty breathing, cough and fever that required immediate treatment.

Frequently Asked Questions

What is the most recent opinion from the FDA on Low Dose Radiation Therapy?

"Low Dose Radiation Therapy has been deemed safe by our team, as it is a Phase 3 trial. This means that there is evidence of efficacy as well as multiple rounds of data supporting safety." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.